.Attribute Medication, Published online: 13 September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized period 3b/4 DESTINY-Breast12 research, trastuzumab deruxtecan (T-DXd) therapy of patients along with HER2+ innovative breast cancer as well as active or even steady mind metastases showed regular intracranial task and wide spread efficiency of T-DXd.